When it comes to science, deep technology, and the advancement of human civilization — China has ambitions not just to compete, but to lead. Don’t miss a beat in China’s steady progress in all things science, health, medicine, and deep technology.
Countries including Indonesia, Brazil, Turkey, and Chile are clamoring for doses of CoronaVac, the vaccine candidate made by Sinovac Biotech. Meanwhile, the maker of another of China’s leading vaccine candidates, Sinopharm, applied last month for market approval.
The Chang’e-5 lunar lander touched down on the Moon today, and will spend two days collecting two kilograms of rocks before returning to Earth in mid-December. If it is successful, China will become the third nation to retrieve lunar samples.
Five Chinese coronavirus vaccines are in Phase 3 clinical trials, but China has not waited for trials to be complete to inject about one million people since July. Preliminary data suggests that China’s vaccines may be less inoculating than those by Pfizer and Moderna.
After a 17-year-old garment factory worker in Kashgar, Xinjiang tested positive for COVID-19, authorities quickly tested all 4.75 million residents of the Kashgar area, finding 164 cases, all without symptoms.
A small COVID-19 cluster has emerged in Qingdao, China, breaking the country’s nearly two-month streak of no locally transmitted symptomatic cases. All nine million Qingdao residents will be screened for the virus this week in response.
China has already vaccinated vast numbers of essential workers and state-owned enterprise employees without a conventional clinical trial process. As soon as this month, however, Beijing may give official approval to a clinically tested vaccine, and begin public rollout in November.
China, under an emergency use authorization, has vaccinated an unspecified number of essential workers outside of clinical trials since July 22, a top health official revealed. At the same time, clinical trials for China’s four COVID-19 vaccine candidates are expanding overseas.
Four vaccines developed by Chinese companies have moved on to Phase 3 trials, accounting for half of the global candidates at that final stage of human testing before approval.
On July 29th Ying Wu shared with us the most recent updates in Chinese tech